Health Condition 1: null- Post orthopaedic surgery patient
Conditions
Interventions
Intervention1: Chymoral Forte: Tablet containing Trypsin:Chymotrypsin (6:1) containing 1,00,000 Armour Units (AU) of enzymatic activity
Dose: One tablet 3 times in a day orally for 7 ? 10 days.
Contr
Sponsors
Elder Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patient of either sex between 18 to 60 years of age 2. Patient to undergo elective clean and uncontaminated surgery for open reduction of fracture 3. Patients willing to take the medications as directed 4. Willing to comply with the protocol requirements 5. Willing to give the written informed consent
Exclusion criteria
Exclusion criteria: 1. Patients with known hypersensitivity to any of the study related drugs (i.e. trypsin-chymotrypsin , serratiopeptidase , Bromelain & Rutoside) 2. Patients undergoing emergency surgery & those with contaminated surgery 3. Patients with known hepatic or renal impairment 4. Patients not willing to give written informed consent 5. Uncontrolled diabetes mellitus or any other metabolic disorder. 6. Pediatric and Pregnant patients. 7. Treatment with any investigational drug in the preceding 4 weeks. 8. Any other condition that, in the opinion of the investigator, does not justify the inclusion of the subject in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite score for surgical wound assessment based on the following symptoms & signs: - Erythema - Local Irritation - Discharge - Edema - Induration - Tenderness Timepoint: Day 3 day 5 day 7 day 10 | — |
Secondary
| Measure | Time frame |
|---|---|
| Pain: Granulation tissue: Global Response Assessment: Timepoint: day 3 day 5 day 7 day 10 | — |
Countries
India
Contacts
Public ContactMr Raj Sethi
Outcome results
None listed